Home Browse Animal Venoms as Potential Source of Anticonvulsants
ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
▬
✚
Review

Animal Venoms as Potential Source of Anticonvulsants

[version 1; peer review: 3 approved]
Syafiq Asnawi Zainal Abidin
https://orcid.org/0000-0002-8249-7668
1, Anthony Kin Yip Liew1, Iekhsan Othman1, Farooq Shaikh2
Syafiq Asnawi Zainal Abidin
https://orcid.org/0000-0002-8249-7668
1, Anthony Kin Yip Liew1, Iekhsan Othman1, Farooq Shaikh2
PUBLISHED 27 Mar 2024
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

Abstract

Abstract*

Epilepsy affects millions of people worldwide, and there is an urgent need to develop safe and effective therapeutic agents. Animal venoms contain diverse bioactive compounds like proteins, peptides, and small molecules, which may possess medicinal properties against epilepsy. In recent years, research has shown that venoms from various organisms such as spiders, ants, bees, wasps, and conus snails have anticonvulsant and antiepileptic effects by targeting specific receptors and ion channels. This review underscores the significance of purified proteins and toxins from these sources as potential therapeutic agents for epilepsy. In conclusion, this review emphasizes the valuable role of animal venoms as a natural resource for further exploration in epilepsy treatment research.

Keywords

Epilepsy, Anticonvulsant, Animal Venom, Bioactive Compounds, GABA, NMDA

Corresponding author: Syafiq Asnawi Zainal Abidin
Competing interests: No competing interests were disclosed.
Grant information: Monash University Malaysia Global Asia in the 21st-Century (GA21) Platform Seed Grant, GA-HW-18-S01
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Copyright:  © 2024 Zainal Abidin SA et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
How to cite: Zainal Abidin SA, Liew AKY, Othman I and Shaikh F. Animal Venoms as Potential Source of Anticonvulsants [version 1; peer review: 3 approved]. F1000Research 2024, 13:225 (https://doi.org/10.12688/f1000research.147027.1) First published: 27 Mar 2024, 13:225 (https://doi.org/10.12688/f1000research.147027.1) Latest published: 27 Mar 2024, 13:225 (https://doi.org/10.12688/f1000research.147027.1)

1. Introduction

Epilepsy is a global epidemic that affects more than 50 million people worldwide, making it one of the most common neurological diseases.1 Almost 80% of epileptic patients come from low- and middle-income countries.1 The Task Force of the International League Against Epilepsy (ILAE) defined epileptic seizure as a transient occurrence of symptoms caused by abnormally excessive brain neuronal activity. Epilepsy is a brain disorder prone to epileptic seizures and consequences from cognitive, neurobiological, psychological, and social aspects.2 There are several types of epileptic seizures, depending on the symptoms. One-third of the epileptic seizures occurred as generalized seizures, whereas two-thirds began as focal seizures. Generalized seizures can be classified into six groups: tonic-clonic, myoclonic, atonic, tonic, clonic, and absence seizures.3 All these symptoms happen without warning and involve loss of consciousness on the patient. Tonic seizures are characterized by constant muscle contraction, while tremors in the limbs indicate clonic seizures. Tonic-clonic seizures have symptoms that combined both tonic and clonic seizures symptoms. The contraction of limb muscles is followed by limb extension and tremors with back arching for around ten to thirty seconds.

Epileptogenesis is the gradual development of epilepsy in a normal brain.4 The causes of epilepsy can be identified as structural or genetics. Structural causes of epilepsy include brain tumors, brain trauma, and other neurodegenerative diseases. Brain areas prone to trauma causing epileptogenesis include structures of the temporal lobe such as the amygdala, hippocampus, and piriform cortex.5 Brain electrical activity is usually non-synchronous in normal humans, while patients suffering from epileptic seizures will have excessive synchronized firing of neuronal firing, which causes a paroxysmal depolarizing shift. Neuronal biochemical receptors play an essential role in epileptogenesis, primarily glutamate receptors (ionotropic and metabotropic). When the receptors are activated, Ca2+ ions will increase within the area of the cells. Therefore, glutamate is seen as one of the most critical molecules in epileptogenesis as it causes excitotoxicity, i.e., neurons are severely depolarised.4

Epilepsy treatment may include drugs, surgery, and even diet changes. The standard first-line therapy for patients newly diagnosed with epilepsy is usually by antiepileptic drugs (AEDs) such as phenobarbital, phenytoin, carbamazepine, or valproic acid. Second line medications such as oxcarbazepine, gabapentin, topiramate, felbamate, and lamotrigine are also applied in the treatment.6 No single AED is proved to be more effective than another, with all drugs producing some side effects depending on the individual treated. These drugs used have a 70% to 80% success rate in treating epilepsy, while the remaining 20% to 30% still suffer from seizures or more significant adverse effects.7

Since epilepsy is caused by the malfunction of ion channels, Gamma-aminobutyric acid (GABA)-ergic neuron inhibition, and excess glutamate release, most AED will target these specific pathways.8 Drugs that target ion channels include carbamazepine, oxcarbazepine, phenytoin, and lamotrigine, which block sodium channels.9 Gabapentin binds on volt-age-dependent calcium channel proteins in rat models and is believed to have GABAergic effects. GABA-mediated inhibition is vital as the binding of GABA to their receptors leads to an influx of negatively charged chloride ions (Cl-) which in turn causes cell hyperpolarisation. Barbiturates and benzodiazepines treat epilepsy by targeting the GABAergic transmission and increasing chloride ion influx.10 Glutamate, which is a primary excitatory neurotransmitter were also believed to play a part in epilepto-genesis. Application of antagonists to the glutamate receptor such as N-methyl-D-aspartate (NMDA) demonstrated anticonvulsant effects in animal models. Valproate, felbamate, and topiramate are NMDA receptor antagonists which are currently used. However, these drugs are known to present several undesirable side effects.8

2. Animal venom as a potential source of anticonvulsants

The earth’s flora and fauna are an important reservoir of naturally derived therapeutic agents. Since ancient times, humans have utilized these resources to treat diseases and improving wellbeing. One significant source is the venom and toxins from venomous and poisonous animals. The venom consists of proteins, enzymes, inorganic ions, and nucleotides, which can induce a plethora of effects, including necrosis, coagulation, haemorrhagic, and neurotoxicity depending on the type of venom.11 Targeted sites of venom are specific and diverse due to the different constitutions and may target receptors and channels such as neuro-junctions and ion channels.12 Animal venom has been regarded as an essential source of potential therapeutic agents in human diseases such as neurodegenerative diseases, cardiovascular diseases, autoimmune diseases, and cancer.13–16 In this literature review, the different types of venom used in treating epilepsy is discussed.

2.1 Spider venom (Table 1)

Neuroprotective potential of various venom fractions and components from venomous spider species has been identified (Table 1). Arylamine-enriched fraction isolated from the venom of funnel-web grass spider Agelenopsis aperta demonstrated significant anticonvulsant properties by antagonizing and blocking NMDA receptor and dihydropyridine (DHP) calcium channels.17 Overexcitation of NMDA receptors and DHP calcium channels were found to be responsible for the pathophysiology of epilepsy.18,19 In the study by Jackson and Parks,17 arylamine-enriched venom fraction was administered both intravenously (i.v.) on male Sprague-Dawley rats induced with epilepsy using kainic acid (KA), picrotoxin (PIC), and bicuculline (BIC). Subjects administered with KA when paired with the venom fractions demonstrated less to nonconvulsive behavior until 70 minutes. Symptoms of seizures subsided after 4 hours with no deaths observed in the 10 subjects. Subjects administered with BIC and PIC paired with the venom fraction (i.v.) also shows closely similar observations and seem mildly sedated at the same time responsive to external stimuli.

Table 1. Anticonvulsive proteins/peptides from spider venom and the mechanism of action.

SpeciesVenom ComponentMechanismReference
Spiders
Agelenopsis apertaAG2NMDA receptor antagonists/blocks dihydropyridine (DHP) sensitive calcium channels17
Parawixia bistrataParawixin 2/FrPBAIIBlocks GABAergic transporters, interferes GABA uptake24,27
Parawixia bistrataParawixin 10Increases glutamate uptake25
Scaptocosa rapto-riaSrTx1Blocks GABAergic transporters, interferes GABA uptake23
Parawixia bistriataPeptide fraction (RT10)In-vitro neuroprotective effect against excitotoxicity26

Active fraction (PbTx1.2.3) from Brazillian orb-weaver spiders Parawixia bistrata demonstrated potential anticonvulsive activity in synaptosomes model from rat cerebral cortex.20 Glutamate and gamma-Amnobutyric acid (GABA) uptake balance is crucial in maintaining normal brain function. Functioning as the primary excitatory neurotransmitter in the brain, the increase of glutamate activity is critical in epileptogenesis.21 In contrast, GABA counterbalances neuronal excitation by acting as the primary inhibitory neurotransmitter. Hence, changes to GABA balance in the brain may trigger seizures.22 PbTx1.2.3 was demonstrated to increase glutamate uptake while inhibiting GABA uptake in cortical synaptosomes in a dose-dependent manner. Drugs that stimulate GABA concentration are potent anticonvulsants such as vigabatrin and tiagabine.22 Moreover, PbTx1.2.3 successfully protected neurons in the rat retinal glaucoma model from excitotoxic death.20 Therefore, PbTx1.2.3 may serve as a template for potential anticonvulsant and neuroprotection drug development.

FrPbAII is another compound found in P. bistrata venom, which was studied for anticonvulsive and anxiolytic properties. Bicuculline was injected into Area-tempestas of male Wistar rats to induce seizures and treated with FrPbAII. The toxin component significantly inhibited seizures elicited by bicuculline. In addition, FrPbAII was demonstrated to block GABAergic transporters that caused epilepsy.23 Animal behavior study using male Wistar rats also showed anticonvulsive properties of FrPbAII. Rats were induced with seizures using pentylenetetrazol and were treated with diazepam, nipecotic acid, and FrPbAII. All subjects treated with diazepam, nipecotic acid, and FrPbAII showed anticonvulsive properties with reduced immobility, increased exploratory walking, rearing, and head-dips than saline control pentylenetetrazole (PTZ)-induced seizure subjects.24

Parawixin-10 is another polyamine found in P. bistrata venom which elicits anticonvulsive properties. Parawixin-10 was administered via i.c.v. injection using a cannula and kainic acid (KA), NMDA, and PTZ to induce seizures. Parawixin-10 demonstrated anticonvulsive properties with the lowest dose required for KA compared to NMDA and PTZ indicating that the mode of action for Parawixin-10 is through the inhibition of excitatory transmission of non-NMDA receptors. Neurochemistry data from the study also showed an increase in L-glutamate and glycine uptake, wherein elevated levels of both compounds are responsible for epilepsy. However, the important mode of action for Parawixin-10 has yet to be pinpointed and thus requires further investigation and studies.25 Additional study on P. bistrata venom fraction, RT10, which comprised of Parawixins 1 and 2, demonstrated neuroprotective effects on neuron-glia primary culture against high L-glutamate concentrations.26

2.2 Scorpion venom

Several subtypes of α and β neurotoxins have been described from the venom of Asian scorpion Buthus martensi Karsch (BmK) (Table 2). These neurotoxins were found to modulate voltage-gated sodium channels (VGSCs).28,29 Antinociceptive effects from BmK venom were demonstrated by the activity of BmK I (α-like neurotoxin) and BmK IT2 (β-like neurotoxins).30,31 A study by Zhao, et al.32 in PTZ and pilocarpine-induced epilepsy rats showed significant anticonvulsant activity from the administration of BmK IT2. The effects of BmK IT2 were attributed to its ability to modulate sodium channels in the hippocampus. A further study with a different toxin from BmK, Bmk-AS, demonstrated similar antiepileptic activities in PTZ and pilocarpine-induced epilepsy in the rat model.33 In another study, a novel peptide synthesised and derived from the Malaysian forest scorpion venom, Hetermetrus spinifer, was shown to reduce inflammation in PTZ-induced epilepsy in-vivo.34 The 25 amino acid peptide named HsTx2 alleviate epilepsy progression by targeting the circ_0001293/miR-8114/TGF- β2 axis, which is responsible for inflammation response in astrocytes.34

Table 2. Anticonvulsive proteins/peptides from scorpion venom and the mechanism of action.

SpeciesVenom ComponentMechanismReference
Scorpions
Buthus martensi KarschBmK IT2Interferes with voltage gated sodium ion channels32
Buthus martensi KarschBmk ASInterferes with voltage gated sodium ion channels33
Heterometrus spiniferHsTx2Regulation of inflammatory responses through the circ_0001293/miR-8114/TGF-β2 axis34

2.3 Bee and Wasp venom

Bee and wasp venom is rich in compounds that act on various biological systems, especially in the nervous system. These compounds include peptides, amines, enzymes, and amino acids (Table 3).35 Both peptides and acyl polyamines have been studied to treat many neurology-related diseases. A single study on mellitin, a major component of the venom from Apis mellifera (honey bee), demonstrated anticonvulsant effects in bicuculine-induced seizures in rats.36 Mellitin could potentially induced its neuroprotective activities via activation of phospholipase A2 and consequently modulating the GABAergic and glutamergic systems.36 Denatured crude venom from Polybia occidentalis (Yellow-banded Polybia wasp) identified dose-dependent effectiveness in treating KA-induced seizures rat model. This finding suggests that venom-induced anticonvulsive activities by antagonizing NMDA-glu receptors. Additional results include in-vivo anticonvulsive effects in rats with PIC- and BIC-induced seizures.37 Recent study on a venom peptide isolated from Polybia occidentalis, occidentalin-1202, pinpointed anti-seizure effects by blocking glutamate and kainic acid interaction with the kainite receptor.38 A different study on the venom of Polybia ignobilis (Brazilian social wasp) demonstrated a similar outcome by preventing seizures induced by KA, PIC, and BIC.39

Table 3. Anticonvulsive proteins/peptides from wasp and bee venom and the mechanism of action.

SpeciesVenom ComponentMechanismReference
Wasps
Polybia occidnetalisDenatured crude venomNMDA receptor antagonists/increases glutamate uptake37
Polybia ignobilisDenatured crude venomInterferes with glutamate and GABA receptors39
Polybia paulistaPeptide fractionsGABA receptors and calcium ion channel interference40
Agelaia vicinaCrude boiled venomInterferes with GABA and glutamate uptake42
Philanthus triangulum F.β-PTx/δ-PTxInhibits glutamate uptake43
Polybia paulistaPpnp7/NeuropolybinNeuroprotective effects against tonic-clonic seizures in PTZ-induced rats41
Polybia occidentalisOccidentalin-1202Inhibit glutamate uptake through blockage of kainate receptors45
Chartergellus communisChartergellus-CP1Postulated to block calcium channels44
Bees
Apis melifferaMelittinIncreases GABA transmission, modulation of glutamatergic neurotransmission36

Low molecular weight fractions of the venom from Polybia paulista (Neotropical social wasp) exhibited anticonvulsant activities in 60% of animals (Wistar rats) induced with PTZ.40 Compared with diazepam treatment, both offer protection from seizures, but the venom demonstrated fewer sedation effects.40 Additionally, peptides isolated from Polybia paulista, Ppnp7 and neuropolybin, demonstrated tonic-clonic seizure protection in 80% of PTZ-induced rats.41 Agelaia vicina venom showed inhibition of GABA and glutamate uptake responsible during epileptogenesis. The venom targeted enzymes accountable for the regulation of ion flow, thus disrupting ion concentration gradient. Additionally, free amino acids were found to inhibit GABA and glutamate uptake.42 Philanthus triangulum F. wasp venom contains components such as β-PTX and δ-PTX, which show effects on animal glutamatergic neuro-junctions. These components were found to inhibit the uptake of glutamate in the neuromuscular synapse on locusts. A study showed a significant decrease in glutamate uptake on hippocampal slices of rats incubated with δ-PTX (74% decrease) and a less significant reduction with incubation in β-PTX (18%). Based on the findings, the venom from Philanthus triangulum F. wasps demonstrated potentials as a source of anticonvulsant agents due to its interference with glutamate uptake, a critical factor in epileptogenesis.43 Besides PTZ-induced seizures, a treatment using wasp venom peptide from Chartegellus communis (Social wasp), Chartergellus-CP1, showed neuroprotective effects in pilocarpine-induced epilepsy.44 In the study, electroencephalographic abnormalities that are associated with pilocarpine-induced seizures were significantly reduced upon administration of Charthergellus-CP1.44

2.4 Ant venom

Ant venom contains an arsenal of molecules that ranges from proteins, peptides, free amino acids, alkaloids, formic acid, and several other organic molecules.46 Like other venomous organisms, the venom has been a subject of interest to uncover its properties and therapeutic potential, including as an anticonvulsive agent (Table 4). The venom of Dinoponera quadriceps (South American giant ant) has been studied for anticonvulsant effects. An initial study by Noga, et al.47 demonstrated the pro-and anticonvulsant effects of the crude venom in-vivo. Injection of crude venom (DqTX) in the lateral ventricle region of mice brain showed procursive behavior and tonic-clonic seizures.

Table 4. Anticonvulsive protein/peptides from ant venom and the mechanism of action.

SpeciesVenom ComponentMechanismReference
Ants
Dinoponera quadricepsCrude venom DqVGABA receptor interference48
Dinoponera quadricepsDqTx 1 – DqTx 6GABA receptor interference49
Dinoponera quadricepsM-PONTX-Dq3a, M-PONTX-Dq3b and M-PONTX-Dq3cDecreased production of reactive oxygen and nitrogen species38

Interestingly, the effects were negated via pre-administration of the same but denatured venom (AbDq), hence, protected the animals against seizures and death.47 Similar results were noted in another study by Lopes, et al.48 Different administration routes of D. quadriceps venom in mice seizure models were responsible for neuroprotective or neurotoxic effects. Intraperitoneal administration of the venom demonstrated increased latency to seizure with an increased survival rate in the PTZ-induced seizure model. In contrast, endovascular treatment-induced neurotoxic effects by reducing the seizure latency time. In another study utilising PTZ-induced seizure model, three different peptides from Dinoponera quadriceps (M-PONTX-Dq3a, M-PONTX-Dq3b, and M-PONTX, Dq3c) also showed anticonvulsant properties by reducing neuroinflammation caused by reactive oxygen species.38

In a subsequent study by Noga, et al.,49 the anticonvulsant effects from the fractions of D. quadriceps crude venom were investigated. The crude venom was fractionated using high-performance liquid chromatography (HPLC) and yielded six fractions labelled DqTX1 – DqTX6. The fractions were administered intracerebroventricularly in BIC-induced seizure rats, and the anticonvulsant effects were determined. DqTX-6 showed significant neuroprotection with 62.5% protection from seizures and 100% protection from death. Since BIC induces seizures by interfering with GABA receptors, the mode of action for the DqTX-6 fraction is most likely to be GABAergic.49

2.5 Conus snail venom

Conopeptides from the venom of marine cone snails belonging to the genus Conus have been identified with potentials as antinociceptive, antiepileptic, neuroprotective, and cardioprotective agents.50 There are at least four peptide families with neuroprotective and cardioprotective activities from Conus snail venom, namely, conantokins, omega-conotoxin (ω-Conotoxin), mu-conotoxin (μ-Conotoxin), and kappa-conotoxin (κ-Conotoxin) (Table 5).51 Conantokins are of particular interest due to their potential in treating epilepsy. Seven types of conantokin peptides were identified, and all were described as NMDA receptor antagonists.52

Table 5. Anticonvulsive proteins/peptides from cone snail venom and the mechanism of action.

SpeciesVenom ComponentMechanismReference
Cone snails
Conus geographusCon-GNMDA receptor blocker57
Conus lynceusCon-LNMDA receptor blocker59
Conus radiatusCon-RNMDA receptor blocker58
Conus magusZiconotideNMDA receptor blocker, N-type calcium channel blocker60

Conantokin-G (Con-G) is a well-studied conantokin from the venom of Geography cone snail Conus geographus. It was advanced into clinical trial phase 1 to treat intractable epilepsy and potential neuro-protectant in ischemic stroke.53 The peptide demonstrated significant antiepileptic activities in animal models of epilepsy, such as maximal electroshock, PTZ induced, and Frings audiogenic seizures.54–56 Anticonvulsive mode of Con-G was via the dose-dependent inhibition of NMDA responses.57 Besides Con-G, Conantokin-R (Con-R) from Conus radiatus Conantokin-L (Con-L) from Conus lynceus showed significant anticonvulsant effects when administered intracerebroventricularly to subjects induced with Frings audiogenic seizures.58,59 Ziconotide, a synthetic derivative of ω-Conotoxin from Conus magus, demonstrated anticonvulsant and anxiolytic effects by potentially reducing extracellular concentrations of glutamate via N-type calcium channel inhibition.60

3. Future directions

The potential of venom as a source of anticonvulsants warrants further exploration and investigation, extending beyond its current focus to encompass other venomous animals which could potentially include snakes. Snake venom is a complex mixture of proteins, peptides, and small molecules that serve as a defence mechanism and aid digestion for snakes towards their prey. Despite its toxicity, snake venom can be an essential source of therapeutic compounds, as demonstrated by its potential in treating cardiovascular disease and as an anti-microbial, anti-viral, anti-fungal, and anti-cancer agent.61 To date, there is only a few studies the anticonvulsant potential of snake venom via Ophiophagus hannah (king cobra) and Micrurus mipartus (Costa Rican coral snake). Saha, et al.62 isolated a non-protein toxin called KC-MMTx from O. hannah crude venom and demonstrated its neuroprotective activity in animal models of epilepsy. KC-MMTx presented significant protection against seizures induced by strychnine, PTZ, and yohimbine, and its potential in interfering with the GABAergic and glycine receptors was touted. Remarkably, toxins from Costa Rican coral snake (MmTX1 and MmTX2) were found to specifically target GABA receptors and significantly improve its sensitivity via allosteric binding.63 Moreover, the ability of snake venom toxins, particularly three-finger toxins (3FTXs), to bind with nicotinic acetylcholine receptors (nAChR) presents another promising avenue in this field. This is noteworthy because the overactivation of nAChR is frequently associated with tonic-clonic convulsions and epilepsy in mammals.64–67 In addition to snake venoms, venoms from sea anemone could also be another important source of therapeutic proteins and peptides as anticonvulsants.68 Several sea anemone toxins extracted from Stichodactyla heliantus, Actinia equina, Anemonia eryhtrae, Anemonia sulcata, Bunodosoma caissarum, Bunodosoma granulifera and Heteractis magnifica were found to selectively target Kv1 channels.69 These findings hold particular importance as Kv1 ion channels play a clinically relevant role in the pathogenesis of neurological diseases, including epilepsy.70

4. Conclusions

Epilepsy remains one of the most critical health burdens in the world. However, the disease currently presents a significant challenge in discovering and developing therapeutic agents that are safe and effective. Venom-based therapeutics has been a subject of focus due to their potential to combat various disorders such as cardiovascular diseases and cancer. This present review demonstrates that animal venom could exert anticonvulsant effects by targeting and regulating specific receptors, modulating uptakes of molecules such as glutamate and glycine, and antagonizing ion channels. In addition, the advancement of proteomic and genomic technology has presented us with the ability to characterize and purify proteins with therapeutic potentials accurately. More proteins/compounds can be isolated and tested in-vivo for anticonvulsant activities. Animal venom represents a promising avenue for researchers to further explore and investigate its compounds as a source of potential antiepileptic/anticonvulsive agents.

Data availability

No data are associated with this article.

Acknowledgements

The authors would like to acknowledge the Monash University Malaysia, Proteomics and Metabolomics Platform and the Jeffrey Cheah School of Medicine and Health Sciences (JCSMHS), Monash University Malaysia for research facilities and publication support.

References

  • 1.  Disease, G.B.DInjury, IPrevalence, C: Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016; 388: 1545–1602. PubMed Abstract | Publisher Full Text | Free Full Text
  • 2.  Fisher RS, Acevedo C, Arzimanoglou A, et al.: ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014; 55: 475–482. PubMed Abstract | Publisher Full Text
  • 3.  Manford M: Recent advances in epilepsy. J. Neurol. 2017; 264: 1811–1824. PubMed Abstract | Publisher Full Text | Free Full Text
  • 4.  McNamara JO, Huang YZ, Leonard AS: Molecular Signaling Mechanisms Underlying Epileptogenesis. Sci. STKE. 2006; 2006: re12–re12. Publisher Full Text
  • 5.  Aroniadou-Anderjaska V, Fritsch B, Qashu F, et al.: Pathology and pathophysiology of the amygdala in epileptogenesis and epilepsy. Epilepsy Res. 2008; 78: 102–116. PubMed Abstract | Publisher Full Text | Free Full Text
  • 6.  Angalakuditi M, Angalakuditi N: A comprehensive review of the literature on epilepsy in selected countries in emerging markets. Neuropsychiatr. Dis. Treat. 2011; 7: 585–597. PubMed Abstract | Publisher Full Text | Free Full Text
  • 7.  French JA, Kanner AM, Bautista J, et al.: Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004; 62: 1261–1273. PubMed Abstract | Publisher Full Text
  • 8.  Nakken K, Heuser K, Alfstad K, et al.: Hvordan virker antiepileptika. Tidsskr. Nor. Laegeforen. 2014; 134: 42–46. PubMed Abstract | Publisher Full Text
  • 9.  Farber N, Jiang X, Heinkel C, et al.: Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity. Mol. Psychiatry. 2002; 7: 726–733. PubMed Abstract | Publisher Full Text
  • 10.  Sutton KG, Martin DJ, Pinnock RD, et al.: Gabapentin inhibits high-threshold calcium channel currents in cultured rat dorsal root ganglion neurons. Br. J. Pharmacol. 2002; 135: 257–265. PubMed Abstract | Publisher Full Text | Free Full Text
  • 11.  Fry BG, Roelants K, Champagne DE, et al.: The toxicogenomic multiverse: convergent recruitment of proteins into animal venoms. Annu. Rev. Genomics Hum. Genet. 2009; 10: 483–511. PubMed Abstract | Publisher Full Text
  • 12.  Gawade SP: Snake venom neurotoxins: Pharmacological classification. J. Toxicol..: Toxin. Rev. 2004; 23: 37–96. Publisher Full Text
  • 13.  Chen N, Xu S, Zhang Y, et al.: Animal protein toxins: origins and therapeutic applications. Biophys. Rep. 2018; 4: 233–242. Publisher Full Text
  • 14.  Zainal Abidin SA, Lee YQ, Othman I, et al.: Malaysian Cobra Venom: A Potential Source of Anti-Cancer Therapeutic Agents. Toxins (Basel). 2019; 11. PubMed Abstract | Publisher Full Text | Free Full Text
  • 15.  Brunner HR, Gavras H, Waeber B, et al.: Clinical use of an orally acting converting enzyme inhibitor: captopril. Hypertension. 1980; 2: 558–566. PubMed Abstract | Publisher Full Text
  • 16.  Ye M, Chung H-S, Lee C, et al.: Neuroprotective effects of bee venom phospholipase A2 in the 3xTg AD mouse model of Alzheimer’s disease. J. Neuroinflammation. 2016; 13: 10. PubMed Abstract | Publisher Full Text | Free Full Text
  • 17.  Jackson H, Parks TN: Anticonvulsant action of an arylamine-containing fraction from Agelenopsis spider venom. Brain Res. 1990; 526: 338–341. PubMed Abstract | Publisher Full Text
  • 18.  Kapur J: Role of NMDA receptors in the pathophysiology and treatment of status epilepticus. Epilepsia open. 2018; 3: 165–168. PubMed Abstract | Publisher Full Text | Free Full Text
  • 19.  Ullal GR: Dihydropyridine group of calcium channel antagonist in epilepsy. Indian J. Physiol. Pharmacol. 1994; 38: 43–46. PubMed Abstract
  • 20.  Fontana ACK, Guizzo R, Beleboni RO, et al.: Purification of a neuroprotective component of Parawixia bistriata spider venom that enhances glutamate uptake. Br. J. Pharmacol. 2003; 139: 1297–1309. PubMed Abstract | Publisher Full Text | Free Full Text
  • 21.  Meldrum BS: The role of glutamate in epilepsy and other CNS disorders. Neurology. 1994; 44: S14–S23. PubMed Abstract
  • 22.  Treiman DM: GABAergic mechanisms in epilepsy. Epilepsia. 2001; 42: 8–12. Publisher Full Text
  • 23.  Cairrão M, Ribeiro AM, Pizzo AB, et al.: Anticonvulsant and GABA uptake inhibition properties of venom fractions from the spiders Parawixia bistriata and Scaptocosa raptoria. Pharm. Biol. 2002; 40: 472–477. Publisher Full Text
  • 24.  Liberato JL, Cunha AO, Mortari MR, et al.: Anticonvulsant and anxiolytic activity of FrPbAII, a novel GABA uptake inhibitor isolated from the venom of the social spider Parawixia bistriata (Araneidae: Araneae). Brain Res. 2006; 1124: 19–27. PubMed Abstract | Publisher Full Text
  • 25.  Fachim HA, Cunha AO, Pereira AC, et al.: Neurobiological activity of Parawixin 10, a novel anticonvulsant compound isolated from Parawixia bistriata spider venom (Araneidae: Araneae). Epilepsy Behav. 2011; 22: 158–164. PubMed Abstract | Publisher Full Text
  • 26.  Primini EO, Liberato JL, Fontana ACK, et al.: Neuroprotective properties of RT10, a fraction isolated from Parawixia bistriata spider venom, against excitotoxicity injury in neuron-glia cultures. J. Venom. Anim. Toxins Incl. Trop. Dis. 2019; 25. Publisher Full Text
  • 27.  Godoy LD, Liberato JL, Celani MVB, et al.: Disease Modifying Effects of the Spider Toxin Parawixin2 in the Experimental Epilepsy Model. Toxins (Basel). 2017; 9. PubMed Abstract | Publisher Full Text | Free Full Text
  • 28.  Goudet C, Chi C-W, Tytgat J: An overview of toxins and genes from the venom of the Asian scorpion Buthus martensi Karsch. Toxicon. 2002; 40: 1239–1258. PubMed Abstract | Publisher Full Text
  • 29.  Zuo X-P, Ji Y-H: Molecular mechanism of scorpion neurotoxins acting on sodium channels. Mol. Neurobiol. 2004; 30: 265–278. PubMed Abstract | Publisher Full Text
  • 30.  Chen J, Tan Z-Y, Zhao R, et al.: The modulation effects of BmK I, an α-like scorpion neurotoxin, on voltage-gated Na+ currents in rat dorsal root ganglion neurons. Neurosci. Lett. 2005; 390: 66–71. PubMed Abstract | Publisher Full Text
  • 31.  Zhang XY, Bai ZT, Chai ZF, et al.: Suppressive effects of BmK IT2 on nociceptive behavior and c-Fos expression in spinal cord induced by formalin. J. Neurosci. Res. 2003; 74: 167–173. PubMed Abstract | Publisher Full Text
  • 32.  Zhao R, Zhang XY, Yang J, et al.: Anticonvulsant effect of BmK IT2, a sodium channel-specific neurotoxin, in rat models of epilepsy. Br. J. Pharmacol. 2008; 154: 1116–1124. PubMed Abstract | Publisher Full Text | Free Full Text
  • 33.  Zhao R, Weng CC, Feng Q, et al.: Anticonvulsant activity of BmK AS, a sodium channel site 4-specific modulator. Epilepsy Behav. 2011; 20: 267–276. PubMed Abstract | Publisher Full Text
  • 34.  Hu Y, Meng B, Yin S, et al.: Scorpion venom peptide HsTx2 suppressed PTZ-induced seizures in mice via the circ_0001293/miR-8114/TGF-β2 axis. J. Neuroinflammation. 2022; 19: 284. PubMed Abstract | Publisher Full Text | Free Full Text
  • 35.  de OBR, Pizzo AB, Fontana AC, et al.: Spider and wasp neurotoxins: pharmacological and biochemical aspects. Eur. J. Pharmacol. 2004; 493: 1–17. PubMed Abstract | Publisher Full Text
  • 36.  Soares-Silva B, Beserra-Filho JIA, Morera PMA, et al.: The bee venom active compound melittin protects against bicuculline-induced seizures and hippocampal astrocyte activation in rats. Neuropeptides. 2022; 91: 102209. PubMed Abstract | Publisher Full Text
  • 37.  Mortari MR, Cunha AOS, De Oliveira L, et al.: Anticonvulsant and behavioural effects of the denatured venom of the social wasp Polybia occidentalis (Polistinae, Vespidae). Basic Clin. Pharmacol. Toxicol. 2005; 97: 289–295. PubMed Abstract | Publisher Full Text
  • 38.  Paes LCF, Lima DB, Silva DMA, et al.: Exploring the neuroprotective potential of antimicrobial peptides from Dinoponera quadriceps venom against pentylenetetrazole-induced seizures in vivo. Toxicon. 2024; 237: 107538. PubMed Abstract | Publisher Full Text
  • 39.  Cunha AO, Mortari MR, Oliveira L, et al.: Anticonvulsant effects of the wasp Polybia ignobilis venom on chemically induced seizures and action on GABA and glutamate receptors. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2005; 141: 50–57. Publisher Full Text
  • 40.  do Couto LL , Dos Anjos LC, Araujo MAF, et al.: Anticonvulsant and anxiolytic activity of the peptide fraction isolated from the venom of the social wasp Polybia paulista. Pharmacogn. Mag. 2012; 8: 292–299. PubMed Abstract | Publisher Full Text | Free Full Text
  • 41.  de Castro e Silva J , Lopes do Couto L, de Oliveira Amaral H , et al.: Neuropolybin: A new antiseizure peptide obtained from wasp venom. Biochem. Pharmacol. 2020; 181: 114119. PubMed Abstract | Publisher Full Text
  • 42.  Pizzo AB, Fontana AC, Coutinho-Netto J, et al.: Effects of the crude venom of the social wasp Agelaia vicina on gamma-aminobutyric acid and glutamate uptake in synaptosomes from rat cerebral cortex. J. Biochem. Mol. Toxicol. 2000; 14: 88–94. PubMed Abstract | Publisher Full Text
  • 43.  van Marle J , Piek T, Lind A, et al.: Reduction of high affinity glutamate uptake in rat hippocampus by two polyamine-like toxins isolated from the venom of the predatory wasp Philanthus triangulum F. Experientia. 1986; 42: 157–158. PubMed Abstract | Publisher Full Text
  • 44.  Lopes KS, Quintanilha MVT, de Souza ACB , et al.: Antiseizure potential of peptides from the venom of social wasp Chartergellus communis against chemically-induced seizures. Toxicon. 2021; 194: 23–36. PubMed Abstract | Publisher Full Text
  • 45.  Mortari MR, Cunha AOS, dos Anjos LC , et al.: A new class of peptides from wasp venom: a pathway to antiepileptic/neuroprotective drugs. Brain Commun. 2023; 5: fcad016. PubMed Abstract | Publisher Full Text | Free Full Text
  • 46.  Touchard A, Aili SR, Fox EGP, et al.: The Biochemical Toxin Arsenal from Ant Venoms. Toxins. 2016; 8: 30. Publisher Full Text
  • 47.  Noga DA, Cagni FC, Santos JR, et al.: Pro- and Anticonvulsant Effects of the Ant Dinoponera quadriceps (Kempf) Venom in Mice. Neotrop. Entomol. 2015; 44: 410–417. PubMed Abstract | Publisher Full Text
  • 48.  Lopes KS, Rios ER, Lima CN, et al.: The effects of the Brazilian ant Dinoponera quadriceps venom on chemically induced seizure models. Neurochem. Int. 2013; 63: 141–145. PubMed Abstract | Publisher Full Text
  • 49.  Noga DA, Brandao LE, Cagni FC, et al.: Anticonvulsant Effects of Fractions Isolated from Dinoponera quadriceps (Kempt) Ant Venom (Formicidae: Ponerinae). Toxins (Basel). 2016; 9: 9. PubMed Abstract | Publisher Full Text | Free Full Text
  • 50.  Han TS, Teichert RW, Olivera BM, et al.: Conus venoms - a rich source of peptide-based therapeutics. Curr. Pharm. Des. 2008; 14: 2462–2479. PubMed Abstract | Publisher Full Text
  • 51.  Twede VD, Miljanich G, Olivera BM, et al.: Neuroprotective and cardioprotective conopeptides: an emerging class of drug leads. Curr. Opin. Drug Discov. Devel. 2009; 12: 231–239. PubMed Abstract
  • 52.  Olivera BM, Cruz LJ, De Santos V, et al.: Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega-conotoxin from Conus magus venom. Biochemistry. 1987; 26: 2086–2090. PubMed Abstract | Publisher Full Text
  • 53.  Malmberg AB, Gilbert H, McCabe RT, et al.: Powerful antinociceptive effects of the cone snail venom-derived subtype-selective NMDA receptor antagonists conantokins G and T. Pain. 2003; 101: 109–116. Publisher Full Text
  • 54.  Williams AJ, Dave JR, Phillips JB, et al.: Neuroprotective efficacy and therapeutic window of the high-affinity N-methyl-D-aspartate antagonist conantokin-G: in vitro (primary cerebellar neurons) and in vivo (rat model of transient focal brain ischemia) studies. J. Pharmacol. Exp. Ther. 2000; 294: 378–386. PubMed Abstract
  • 55.  Lu XC, Williams AJ, Wagstaff JD, et al.: Effects of delayed intrathecal infusion of an NMDA receptor antagonist on ischemic injury and peri-infarct depolarizations. Brain Res. 2005; 1056: 200–208. PubMed Abstract | Publisher Full Text
  • 56.  Williams AJ, Ling G, Berti R, et al.: Treatment with the snail peptide CGX-1007 reduces DNA damage and alters gene expression of c-fos and bcl-2 following focal ischemic brain injury in rats. Exp. Brain Res. 2003; 153: 16–26. PubMed Abstract | Publisher Full Text
  • 57.  Donevan SD, McCabe RT: Conantokin G Is an NR2B-Selective Competitive Antagonist of N-Methyl-d-aspartate Receptors. Mol. Pharmacol. 2000; 58: 614–623. PubMed Abstract | Publisher Full Text
  • 58.  White HS, McCabe RT, Armstrong H, et al.: In vitro and in vivo characterization of conantokin-R, a selective NMDA receptor antagonist isolated from the venom of the fish-hunting snail Conus radiatus. J. Pharmacol. Exp. Ther. 2000; 292: 425–432. PubMed Abstract
  • 59.  Jimenez EC, Donevan S, Walker C, et al.: Conantokin-L, a new NMDA receptor antagonist: determinants for anticonvulsant potency. Epilepsy Res. 2002; 51: 73–80. PubMed Abstract | Publisher Full Text
  • 60.  Zamani M, Budde T, Bozorgi H: Intracerebroventricular administration of N-type calcium channel blocker ziconotide displays anticonvulsant, anxiolytic, and sedative effects in rats: A preclinical and pilot study. Epilepsy Behav. 2020; 111: 107251. PubMed Abstract | Publisher Full Text
  • 61.  Zainal Abidin SA, Lee YQ, Othman I, et al.: Malaysian Cobra Venom: A Potential Source of Anti-Cancer Therapeutic Agents. Toxins. 2019; 11: 75. PubMed Abstract | Publisher Full Text | Free Full Text
  • 62.  Saha A, Gomes A, Chakravarty AK, et al.: CNS and anticonvulsant activity of a non-protein toxin (KC-MMTx) isolated from King Cobra (Ophiophagus hannah) venom. Toxicon. 2006; 47: 296–303. Publisher Full Text
  • 63.  Rosso JP, Schwarz JR, Diaz-Bustamante M, et al.: MmTX1 and MmTX2 from coral snake venom potently modulate GABAA receptor activity. Proc. Natl. Acad. Sci. USA. 2015; 112: E891–E900. PubMed Abstract | Publisher Full Text | Free Full Text
  • 64.  Nirthanan S, Awal W, Niranjan NR: Snake a-Neurotoxins and the Nicotinic Acetylcholine Receptor. Snake Venoms. 2017; 215. Publisher Full Text
  • 65.  Dixit KS, Dhasmana KM, Saxena RC, et al.: Antagonism of intracerebrally induced nicotinic convulsions in mice: A method for measuring the central antinicotinic activity of CNS acting agents. Psychopharmacologia. 1971; 19: 67–72. Publisher Full Text
  • 66.  Becchetti A, Grandi LC, Cerina M, et al.: Nicotinic acetylcholine receptors and epilepsy. Pharmacol. Res. 2023; 189: 106698. PubMed Abstract | Publisher Full Text
  • 67.  Son L, Kryukova E, Ziganshin R, et al.: Novel Three-Finger Neurotoxins from Naja melanoleuca Cobra Venom Interact with GABAA and Nicotinic Acetylcholine Receptors. Toxins. 2021; 13: 164. PubMed Abstract | Publisher Full Text | Free Full Text
  • 68.  Madio B, King GF, Undheim EAB: Sea Anemone Toxins: A Structural Overview. Mar. Drugs. 2019; 17. PubMed Abstract | Publisher Full Text | Free Full Text
  • 69.  Finol-Urdaneta RK, Belovanovic A, Micic-Vicovac M, et al.: Marine Toxins Targeting Kv1 Channels: Pharmacological Tools and Therapeutic Scaffolds. Mar. Drugs. 2020; 18: 173. PubMed Abstract | Publisher Full Text | Free Full Text
  • 70.  Allen NM, Weckhuysen S, Gorman K, et al.: Genetic potassium channel-associated epilepsies: Clinical review of the K(v) family. Eur. J. Paediatr. Neurol. 2020; 24: 105–116. PubMed Abstract | Publisher Full Text

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 27 Mar 2024
Comment
Author details Author details
Competing interests
Grant information
Article Versions (1)
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
 - -
Citations
SEE MORE DETAILS
CITE
how to cite this article
Zainal Abidin SA, Liew AKY, Othman I and Shaikh F. Animal Venoms as Potential Source of Anticonvulsants [version 1; peer review: 3 approved]. F1000Research 2024, 13:225 (https://doi.org/10.12688/f1000research.147027.1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 27 Mar 2024
Views
3
Cite
Reviewer Report 08 Jul 2024
Zhijian Cao, Wuhan University, Wuhan, Hubei, China 
Approved
VIEWS 3
https://doi.org/10.5256/f1000research.161164.r293545
This is a short review about Animal Venoms as Potential Source of Anticonvulsants written by Syafiq Asnawi Zainal Abidin, Anthony Kin Yip Liew, Iekhsan Othman, and Farooq Shaikh. Epilepsy is a global epidemic that affects more than 50 million people ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Cao Z. Reviewer Report For: Animal Venoms as Potential Source of Anticonvulsants [version 1; peer review: 3 approved]. F1000Research 2024, 13:225 (https://doi.org/10.5256/f1000research.161164.r293545)
The direct URL for this report is:
https://f1000research.com/articles/13-225/v1#referee-response-293545
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Report a concern
Views
2
Cite
Reviewer Report 24 Jun 2024
Cletus Anes Ukwubile, University of Maiduguri, Maiduguri, Borno, Nigeria 
Approved
VIEWS 2
https://doi.org/10.5256/f1000research.161164.r293539
The author has rightly included in the review most essential parameters. This review draws the attention of the audience on the potentials of venom as anticonvulsant agent.
The language use was concise and interesting. However, there is the need ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Ukwubile CA. Reviewer Report For: Animal Venoms as Potential Source of Anticonvulsants [version 1; peer review: 3 approved]. F1000Research 2024, 13:225 (https://doi.org/10.5256/f1000research.161164.r293539)
The direct URL for this report is:
https://f1000research.com/articles/13-225/v1#referee-response-293539
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Report a concern
Views
5
Cite
Reviewer Report 17 May 2024
Benedict C Offor, University of Johannesburg, Auckland Park, Johannesburg, South Africa 
Approved
VIEWS 5
https://doi.org/10.5256/f1000research.161164.r276839
A review entitled Animal venoms as a potential source of anticonvulsants by Zainal Abidin and colleagues is very exciting and informative. Considering the challenges and stereotypes associated with the sufferers of epilepsy, there is a need to explore natural sources ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Offor BC. Reviewer Report For: Animal Venoms as Potential Source of Anticonvulsants [version 1; peer review: 3 approved]. F1000Research 2024, 13:225 (https://doi.org/10.5256/f1000research.161164.r276839)
The direct URL for this report is:
https://f1000research.com/articles/13-225/v1#referee-response-276839
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Report a concern

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 27 Mar 2024
Comment

Open Peer Review

Reviewer Status

Alongside their report, reviewers assign a status to the article:

Approved
The paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations
A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved
Fundamental flaws in the paper seriously undermine the findings and conclusions

Reviewer Reports

Invited Reviewers
1 2 3
Version 1
27 Mar 24 		read read read
  1. Benedict C Offor, University of Johannesburg, Auckland Park, Johannesburg, South Africa
  2. Cletus Anes Ukwubile, University of Maiduguri, Maiduguri, Nigeria
  3. Zhijian Cao, Wuhan University, Wuhan, China

Comments on this article

All Comments(0)

Add a comment
Sign up for content alerts

Browse by related subjects

    keyboard_arrow_left Back to all reports
    keyboard_arrow_left Back to all reports
    keyboard_arrow_left Back to all reports
    Alongside their report, reviewers assign a status to the article:
    Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
    Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
    Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
    Sign In
    If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

    The email address should be the one you originally registered with F1000.
    Email address not valid, please try again

    You registered with F1000 via Google, so we cannot reset your password.

    To sign in, please click here.

    If you still need help with your Google account password, please click here.

    You registered with F1000 via Facebook, so we cannot reset your password.

    To sign in, please click here.

    If you still need help with your Facebook account password, please click here.

    Code not correct, please try again
    Email us for further assistance.
    Server error, please try again.